Valuation: Lundbeck

Market Cap 41.78B 6.41B 5.59B 5.28B 4.79B 8.98B 615B 9.01B 63.21B 24.39B 313B 24.07B 23.54B 1,006B P/E 2026 *
9.37x
P/E 2027 * 9.18x
Enterprise Value 45.78B 7.02B 6.12B 5.78B 5.25B 9.84B 674B 9.88B 69.26B 26.73B 343B 26.38B 25.79B 1,102B EV / Sales 2026 *
1.77x
EV / Sales 2027 * 1.6x
Free-Float
30.74%
Yield 2026 *
3.65%
Yield 2027 * 3.3%
1 day+2.66%
1 week-7.53%
Current month-3.11%
1 month-3.46%
3 months+10.66%
6 months+21.08%
Current year+11.88%
1 week 38.75
Extreme 38.75
44.75
1 month 38.75
Extreme 38.75
45
Current year 31.4
Extreme 31.4
45
1 year 31.4
Extreme 31.4
45
3 years 23.3
Extreme 23.3
45
5 years 21.94
Extreme 21.935
45
10 years 21.94
Extreme 21.935
45
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2023
Director of Finance/CFO 49 01/09/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 25/03/2015
Director/Board Member 67 25/03/2015
Director/Board Member 60 20/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
+2.66%-7.53% - - 6.41B
-0.56%-0.78%+25.25%+102.43% 102B
-0.42%-3.92%+50.66%+155.36% 52.42B
+2.00%-3.04%-15.56%+235.53% 20.85B
-1.61%-2.39%-11.32%-11.42% 7.88B
-0.19%-0.61%-37.33%-36.05% 6.83B
-0.19%-4.19%-5.42%+14.96% 6.41B
-0.07%-2.21%-18.33%-33.10% 5.97B
-1.57%-1.63%-3.55%+18.18% 4.94B
-2.92%+0.71%+12.05%+9.93% 3.79B
Average -0.29%-2.06%-0.40%+50.65% 23.45B
Weighted average by Cap. -0.25%-1.71%+21.06%+109.87%

Financials

2026 *2027 *
Net sales 25.91B 3.97B 3.47B 3.27B 2.97B 5.57B 381B 5.59B 39.2B 15.13B 194B 14.93B 14.6B 624B 26.03B 3.99B 3.48B 3.29B 2.99B 5.59B 383B 5.62B 39.38B 15.2B 195B 15B 14.67B 627B
Net income 4.58B 703M 613M 579M 525M 984M 67.43B 989M 6.93B 2.67B 34.28B 2.64B 2.58B 110B 4.66B 714M 623M 588M 534M 1B 68.54B 1B 7.05B 2.72B 34.85B 2.68B 2.62B 112B
Net Debt 4B 614M 535M 506M 459M 860M 58.92B 864M 6.06B 2.34B 29.96B 2.31B 2.26B 96.39B -178M -27.26M -23.77M -22.45M -20.38M -38.19M -2.62B -38.35M -269M -104M -1.33B -102M -100M -4.28B
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
18/09/26 DKK 40.50 +2.66% 98,682
17/09/26 DKK 39.45 +0.25% 110,155
16/09/26 DKK 39.35 -4.61% 167,291
15/09/26 DKK 41.25 -6.04% 233,871
14/09/26 DKK 43.90 +0.23% 213,220
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
42.56DKK
Average target price
48.58DKK
Spread / Average Target
+14.14%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!